XRTXHealthcare · Biotechnology

XRTX Stock Forecast: XORTX Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026

$1.85

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 8 Oct 2026 — in the weakest quartile.

Market cap

$3.2M

Ticker Nerd rank

14 / 100

Median analyst target

—

Analysts covering

Revenue$0.0

Operating income−$1.7M

Net income−$1.7M

Free cash flow−$3.4M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Ticker Nerd rank

XRTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores XORTX Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026

14 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Volatility

Issuance

Momentum

Growth

Revisions

Quality

Value

Accruals

Size (97): Smaller than most of the companies we track.

Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XRTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XRTX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Recent analyst actionsNewest first

Of the 8 most recent actions, 3 moved their price target up and 3 moved it down.

Date	Firm	Action	Rating	Target
4 Jan 2024	Alliance Global Partners	Maintains	Buy	$9.00 → $14
22 Dec 2021	Alliance Global Partners	Initiates	Buy	—
9 Dec 2021	Alliance Global Partners	Initiates	Buy	—
3 Oct 2012	Cantor Fitzgerald	Maintains	Hold	$11 → $8.50
28 Sept 2012	Cantor Fitzgerald	Maintains	Hold	$12 → $11
6 July 2012	BMO Capital	Maintains	Market Perform	$15 → $12
30 Mar 2012	Brean Capital	Maintains	Buy	$18 → $20
23 Mar 2012	BMO Capital	Maintains	Market Perform	$13 → $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XRTX appears on the weeks it earns a place.

Estimates

XRTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

XORTX Therapeutics, Inc. (XRTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 7.5×
Price / sales: —
Price / book: 1.2×
EV / EBITDA: −1.0×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −99.2%
Return on assets: −29.9%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

XORTX Therapeutics, Inc. (XRTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

XORTX Therapeutics, Inc. has a market value of $3.2M and an enterprise value of $2.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$3.7M.
Free cash flow in the twelve months to 30 June 2026: −$5.3M.
Shares outstanding: 1.7M.
Trailing P/E: 7.5×; forward P/E: 2.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
XORTX Therapeutics, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

XRTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
XRTXXORTX Therapeutics, Inc.	$3.2M	14
CMNDClearmind Medicine, Inc.	$3.3M	6
SLXNSilexion Therapeutics Corp.	$3.4M	56
CVKDCadrenal Therapeutics, Inc.	$3.3M	34
SXTP60 Degrees Pharmaceuticals, Inc.	$3.4M	37
HCWBHCW Biologics Inc.	$3.4M	57
KAPAKairos Pharma Ltd.	$3.2M	37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own XORTX Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XRTX news & analysis

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

GlobeNewsWire · 18 Sept 2026positive

XORTX announced a planned Investigational New Drug (IND) application submission to the U.S. FDA in the fourth quarter of 2026 for its XRx-026 gout program. The company said this advances its regulatory path toward a New Drug Application filing for the program.

Why it matters — For XORTX watchers, this announcement signals progress in the company's regulatory timeline for its XRx-026 gout program toward a future FDA filing.

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

GlobeNewsWire · 10 Sept 2026positive

XORTX Therapeutics announced the start of clinical and commercial manufacturing of XORLO. Contract manufacturing covers GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval.

Why it matters — This marks a step forward in XORTX's production capacity for XORLO, supporting its ongoing clinical study and potential path toward FDA marketing approval.

XORTX Re-Engages Investor Relations Program

GlobeNewsWire · 8 Sept 2026neutral

XORTX Therapeutics announced it has re-engaged IR Agency LLC for investor relations and marketing services following the completion of its voluntary delisting from the TSX Venture Exchange. The new consulting agreement is on substantially the same terms previously disclosed in the Company's news releases dated May 19, 2026 and August 28, 2026.

Why it matters — XORTX watchers would care because the re-engagement signals the Company is proactively continuing its investor relations and outreach efforts after completing its delisting from the TSX Venture Exchange.

XORTX Announces Termination and Postponement of Investor Relations Program

GlobeNewsWire · 28 Aug 2026neutral

XORTX Therapeutics announced it terminated its investor relations and marketing agreement with IR Agency LLC effective August 7, 2026. Under mutual agreement the arrangement was rescinded, all services were discontinued, and the US$2.5 million previously paid to IR Agency LLC was returned to the Company on August 14, 2026.

Why it matters — XORTX watchers would note that the US$2.5 million allocated from the May 2026 public offering to marketing and advertising has been returned to the Company, ending the previously disclosed IR program.

XORTX Announces Director Resignation

GlobeNewsWire · 31 July 2026neutral

XORTX Therapeutics announced that board director Anthony Giovinazzo is resigning for personal reasons and to pursue other interests. The company expressed appreciation for his contributions.

Why it matters — A director resignation can signal a change in board composition and governance, which shareholders may monitor for any impact on company oversight.

FAQ

Frequently asked questions about XRTX stock

Is XRTX stock a buy right now?

Of the 1 analysts covering XORTX Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks XORTX Therapeutics, Inc. 14 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XRTX?

As at 8 Oct 2026, XORTX Therapeutics, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the XRTX stock forecast for 2030?

No analyst covering XORTX Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XRTX are extrapolating price history, which says nothing about the business.

What does XORTX Therapeutics, Inc. do?

What is the latest news on XRTX?

The most recent item we track (GlobeNewsWire, 18 Sept 2026): "XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity". XORTX announced a planned Investigational New Drug (IND) application submission to the U.S. FDA in the fourth quarter of 2026 for its XRx-026 gout program. The company said this advances its regulatory path toward a New Drug Application filing for the program.

Company

About XORTX Therapeutics, Inc.

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies for gout, progressive kidney disease, and other disorders linked to elevated uric acid and abnormal purine metabolism. Its current pipeline includes programs for gout, autosomal dominant polycystic kidney disease, acute kidney injury associated with respiratory virus infections, and type 2 diabetic nephropathy. The company’s research centers on uric acid-lowering and xanthine oxidase-targeted approaches designed to address conditions ranging from rare kidney diseases to broader metabolic and renal disorders. Based in Calgary, Canada, XORTX Therapeutics Inc. operates as a biotechnology and pharmaceutical developer with an emphasis on advancing drug candidates through clinical development and commercialization in specialized disease areas.

CEO Dr. Allen Warren Davidoff Ph.D. · 2 employees · Canada · https://www.xortx.com